-
公开(公告)号：US20240308954A1
公开(公告)日：2024-09-19
申请号：US18549986
申请日：2022-03-11
申请人： BIOMEDCODE HELLAS SA
发明人： George Kollias , Niki Karagianni , Maria C. Denis , Alexios N. Matralis , Dimitra Papadopoulou , Eleni Karkoulia
IPC分类号： C07C237/44 , A61K31/166 , A61K31/353 , A61K31/44 , A61K31/4418 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P29/00 , C07C231/02 , C07D211/38 , C07D213/40 , C07D213/82 , C07D241/44 , C07D295/135 , C07D311/58 , C07D471/04
CPC分类号： C07C237/44 , A61K31/166 , A61K31/353 , A61K31/44 , A61K31/4418 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P29/00 , C07C231/02 , C07D211/38 , C07D213/40 , C07D213/82 , C07D241/44 , C07D295/135 , C07D311/58 , C07D471/04 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18
摘要： A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or isomer thereof. Pharmaceutical compositions comprising the compounds of formula (I) as well as their use in therapy, particularly in the treatment of inflammatory conditions. Advantageously, the compounds show a broad and robust anti-inflammatory effect, and are therapeutically safe.
-
公开(公告)号：US11951137B2
公开(公告)日：2024-04-09
申请号：US17206851
申请日：2021-03-19
发明人： Yuanlong Pan
IPC分类号： A61K36/00 , A23D9/007 , A23K10/18 , A23K20/158 , A23K50/40 , A23L33/115 , A23L33/12 , A23L33/175 , A61K31/198 , A61K31/20 , A61K31/202 , A61K31/22 , A61K31/4375 , A61K31/445 , A61K31/454 , A61K31/522 , A61K31/54 , A61K31/55 , A61K31/56 , A61K31/663 , A61K31/675 , A61K31/683 , A61K35/60 , A61K36/16 , A61K45/06
CPC分类号： A61K35/60 , A23D9/007 , A23K10/18 , A23K20/158 , A23K50/40 , A23L33/115 , A23L33/12 , A23L33/175 , A61K31/198 , A61K31/20 , A61K31/202 , A61K31/22 , A61K31/4375 , A61K31/445 , A61K31/454 , A61K31/522 , A61K31/54 , A61K31/55 , A61K31/56 , A61K31/663 , A61K31/675 , A61K31/683 , A61K36/16 , A61K45/06 , A61K31/20 , A61K2300/00 , A61K31/22 , A61K2300/00 , A61K31/54 , A61K2300/00 , A61K31/202 , A61K2300/00 , A61K31/4375 , A61K2300/00 , A61K31/445 , A61K2300/00 , A61K31/454 , A61K2300/00 , A61K31/522 , A61K2300/00 , A61K31/55 , A61K2300/00 , A61K31/56 , A61K2300/00 , A61K31/663 , A61K2300/00 , A61K31/675 , A61K2300/00 , A61K31/683 , A61K2300/00 , A61K36/16 , A61K2300/00
摘要： Compositions include arginine and one or more unsaturated fatty acids. Methods for using such compositions can enhance cognitive function, reduce or prevent a decline of social interaction, reduce or prevent age-related behavioral changes, increase trainability, maintain optimal brain function, facilitate learning and memory, reduce memory loss, retard brain aging, prevent or treat strokes, and/or prevent or treat dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.
-
公开(公告)号：US11911393B2
公开(公告)日：2024-02-27
申请号：US18169785
申请日：2023-02-15
申请人： University of Maryland, Baltimore , The United States of America as represented by the Department of Veterans Affairs
摘要： Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
-
4.发明公开公开(公告)号：US20240000794A1
公开(公告)日：2024-01-04
申请号：US18253664
申请日：2021-11-19
发明人： Patrice SOUMILLION , Pierre GALKA
摘要： Lactam or lactone derivatives of formula Ia:
or a pharmaceutically acceptable salt or solvate thereof, wherein X1 is NH or O; X2 is —OH, —O-alkyl, —NH2, an amino acid group or a peptide group, wherein the amino acid group or peptide group is linked to the carbonyl group by its N-terminal residue; Z1 is S, SO, SO2, O, CR3 or NR4; and R1, R2, R3 and R4 each independently are H, alkyl or aryl. Also, the use of lactam or lactone derivatives of formula Ia in treating a disease caused by a viral infection, especially a coronavirus infection and/or a viral respiratory infection, such as COVID-19 caused by SARS-CoV-2.-
公开(公告)号：US20230285573A1
公开(公告)日：2023-09-14
申请号：US17935297
申请日：2022-09-26
发明人： Aseem ANSARI , Pratik SHAH
IPC分类号： A61K47/59 , A61K31/454 , A61K31/4545 , A61K31/4704 , A61K31/50 , A61K31/502 , A61K31/5025 , A61K31/54 , A61K48/00 , A61K47/54 , A61K47/60 , A61K47/22 , A61K47/56 , A61K31/519 , A61K31/517
CPC分类号： A61K47/595 , A61K31/454 , A61K31/4545 , A61K31/4704 , A61K31/50 , A61K31/502 , A61K31/5025 , A61K31/54 , A61K48/0066 , A61K47/54 , A61K47/60 , A61K47/22 , A61K47/56 , A61K31/519 , A61K31/517
摘要： The present disclosure relates to compounds and methods for modulating the expression of bean (brain expressed, associated with NEDD4) and treating diseases and conditions in which bean plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence TGGAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence TGGAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
-
公开(公告)号：US20230233551A1
公开(公告)日：2023-07-27
申请号：US17815256
申请日：2022-07-27
发明人： Thomas GADEK , John BURNIER
IPC分类号： A61K31/4725 , C07D217/00 , C07D217/02 , A61K31/198 , A61K31/404 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/5377 , A61K31/54 , A61K31/541 , A61P27/02 , A61K31/381 , A61K45/06 , C07D333/38 , C07D405/06 , C07D405/14 , C07D409/14 , C07D471/04 , A61K33/00 , A61K33/06 , C07D217/20 , C07D217/06 , A61K31/405 , A61K31/495 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/17 , G01N33/50 , G01N33/68 , A61K31/197 , A61K31/341 , A61K31/352 , A61K31/472 , C07D401/06 , A61K31/275 , A61K31/40 , A61K31/517 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/26 , C07D307/52 , C07D413/14 , A61K9/00 , G01N33/566 , A61B3/10 , A61B3/14
CPC分类号： A61K31/4725 , C07D217/00 , C07D217/02 , A61K31/198 , A61K31/404 , A61K31/4162 , A61K31/4184 , A61K31/4192 , A61K31/44 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/5377 , A61K31/54 , A61K31/541 , A61P27/02 , A61K31/381 , A61K45/06 , C07D333/38 , C07D405/06 , C07D405/14 , C07D409/14 , C07D471/04 , A61K33/00 , A61K33/06 , C07D217/20 , C07D217/06 , A61K31/405 , A61K31/495 , A61K38/07 , A61K38/08 , A61K38/12 , A61K38/1703 , G01N33/5011 , G01N33/5032 , G01N33/6872 , A61K31/197 , A61K31/341 , A61K31/352 , A61K31/472 , C07D401/06 , G01N33/5047 , A61K31/275 , A61K31/40 , A61K31/517 , C07C279/28 , C07C317/50 , C07D207/06 , C07D217/26 , C07D307/52 , C07D413/14 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0048 , A61K9/0053 , G01N33/566 , A61B3/101 , A61K9/0051 , A61B3/145 , G01N2333/70525 , G01N2500/02 , G01N2500/10 , G01N2333/705 , G01N2333/70546 , G01N2500/20 , G01N2500/04 , G01N2800/16
摘要： The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
-
公开(公告)号：US20230165875A1
公开(公告)日：2023-06-01
申请号：US17997758
申请日：2021-04-30
摘要： The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.
-
公开(公告)号：US11654149B2
公开(公告)日：2023-05-23
申请号：US17353717
申请日：2021-06-21
发明人： Leonard I. Zon , Alison M. Taylor
IPC分类号： A61K31/553 , A61K31/495 , A61K31/4965 , A61K31/54 , A61K31/5415 , A61K31/145 , A61K31/4184 , A61K31/4375 , A61K31/4418
CPC分类号： A61K31/553 , A61K31/145 , A61K31/4184 , A61K31/4375 , A61K31/4418 , A61K31/495 , A61K31/4965 , A61K31/54 , A61K31/5415
摘要： The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
-
公开(公告)号：US11590141B2
公开(公告)日：2023-02-28
申请号：US16981029
申请日：2019-03-15
发明人： Ko Kobayakawa , Reiko Kobayakawa
摘要： The present invention provides a prophylactic or therapeutic agent for hypoxic injury, ischemia-reperfusion injury or inflammation, an agent for protecting cells for transplantation, and an agent for preserving organism. A prophylactic or therapeutic agent for hypoxic injury, ischemia-reperfusion injury or inflammation, an agent for protecting cells for transplantation, or an agent for preserving organism, containing, as an active ingredient, at least one kind selected from a heterocyclic compound represented by the formula (I) wherein each symbol is as described in the DESCRIPTION, or a salt thereof; an isothiocyanate compound represented by the formula S═C═N—R5 (II) wherein the symbol is as described in the DESCRIPTION; and a TRPA1 agonist.
-
公开(公告)号：US20230000813A1
公开(公告)日：2023-01-05
申请号：US17807984
申请日：2022-06-21
申请人： Intervet Inc.
IPC分类号： A61K31/27 , A61P31/04 , A61P11/00 , A61K9/00 , A61K31/166 , A61K31/222 , A61K31/357 , A61K31/40 , A61K31/445 , A61K31/472 , A61K31/495 , A61K31/5377 , A61K31/54 , A61K31/695
摘要： The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
-
-
-
-
-
-
-
-
-
搜索结果
2872 条记录 (耗时 0.069 秒)
